Mikael Oerum appointed Member of the Scientific Advisory Board of Virginia Bioinformatics Institute at Virginia Tech, USA.
We participate in numerous events promoting our portfolio companies and meeting our clients.
APIM Therapeutics, a Ventac Partners portfolio company, secures follow up seed funding from Birk Venture, Ro Invest and Sarsia Seed with the support of Ventac Partners.
Ventac Partners completes a strategic business and market analysis for HUNT Biosciences, the commercial arm of the largest population based biobank in Norway.
Ventac Partners is co-founder of Zestagen S.A., a company focusing on the development of novel anti-cancer treatments. Martin Austin becomes the Chairman of the Board. The company secures seed funding up to USD 1.4 million.
Regenesance, a Ventac Partners portfolio company, receives innovation credit from Dutch Government. The Dutch Ministry of Economic Affairs and Innovation (Agentschap, NL) awarded a substantial credit to Regenesance for the development of new compounds to treat Multiple Sclerosis. The credit will provide up to 35% of the costs advancing a lead compound through clinical phase IIa. Total support could approach USD 5 million.
Mikael Oerum appointed Chairman of the Board of HUNT Biosciences AS. HUNT Biosciences is owned by the Norwegian Institute of Science and technology, the Health Region Mid-Norway and the Trøndelag County of Norway.